Østensen M
Department of Rheumatology and Clinical Immunology/Allergology, University Hospital of Berne, Switzerland.
Best Pract Res Clin Obstet Gynaecol. 2001 Dec;15(6):953-69. doi: 10.1053/beog.2001.0240.
Rheumatic diseases occur frequently in women of childbearing years, necessitating drug treatment during a concurrent pregnancy in order to control maternal disease activity and to ensure a successful pregnancy outcome. Inflammatory rheumatic diseases with mainly musculoskeletal involvement may cause acute episodes of arthritis. Autoimmune, systemic diseases may flare with manifestations of haematological, dermatological or renal disease or give rise to thromboembolism during pregnancy. Treatment with non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, immunosuppressive or even cytotoxic drugs may be required to acquire disease control. Unfortunately, controlled studies on the use of antirheumatic drugs during gestation exist only for a few drugs. This chapter presents data on the use of antirheumatic drugs during pregnancy, addressing the risk of teratogenicity, possible long-term effects on the infant exposed to drugs antenatally, and maternal side-effects which interfere with pregnancy. Recommendations for pre-pregnancy counselling and necessary adjustment of drug treatment before and during pregnancy are given.
风湿性疾病在育龄女性中频繁发生,因此在孕期需要进行药物治疗,以控制母体疾病活动并确保妊娠成功。主要累及肌肉骨骼的炎性风湿性疾病可能引发关节炎急性发作。自身免疫性全身性疾病在孕期可能会出现血液学、皮肤病学或肾脏疾病表现而病情加重,或引发血栓栓塞。为控制病情,可能需要使用非甾体抗炎药、皮质类固醇、抗凝剂、免疫抑制剂甚至细胞毒性药物进行治疗。遗憾的是,关于妊娠期使用抗风湿药物的对照研究仅针对少数几种药物。本章介绍了妊娠期使用抗风湿药物的数据,探讨了致畸风险、对产前接触药物的婴儿可能产生的长期影响以及干扰妊娠的母体副作用。文中还给出了孕前咨询建议以及孕期前后药物治疗的必要调整。